卡博替尼联合替莫唑胺治疗不可切除或转移性平滑肌肉瘤及其他软组织肉瘤:多中心单臂先导性2期试验
这项多中心单臂先导性2期试验评估卡博替尼联合替莫唑胺治疗不可切除或转移性平滑肌肉瘤及其他软组织肉瘤的疗效与安全性。联合方案耐受可,未发现新安全信号。
要点
- 卡博替尼联合替莫唑胺在不可切除或转移性平滑肌肉瘤中显示有意义的临床获益。
- 常见3-4级不良事件为血小板减少(30%)、中性粒细胞减少(18%)、高血压(10%)和腹泻(8%)。
核心结论
- 卡博替尼联合替莫唑胺在不可切除或转移性平滑肌肉瘤中显示出有意义的临床获益,可能成为可行的治疗选择。
- 治疗耐受性良好,未发现新的安全性信号。
研究设计与样本
- 多中心、单臂、先导性2期试验,在美国中西部肉瘤试验联盟的五家学术肉瘤卓越中心开展。
- 入组72例患者,分为队列1(子宫及非子宫平滑肌肉瘤,n=42)和队列2(其他软组织肉瘤,探索性,n=30)。
- 主要终点为队列1意向治疗人群的12周无进展生存期。
主要发现
- 队列1中31例(74%)患者在第12周时仍在接受卡博替尼和替莫唑胺治疗。
- 研究结束时,队列1有20例(48%)、队列2有23例(77%)患者因疾病进展死亡。
- 71例(99%)患者发生≥1级治疗相关不良事件。
关键数值与推荐
- 卡博替尼起始剂量为40 mg口服每日一次。
- 常见3-4级不良事件:血小板减少22例(30%)、中性粒细胞减少13例(18%)、高血压7例(10%)、腹泻6例(8%)。
临床怎么用
- 对于不可切除或转移性平滑肌肉瘤患者,卡博替尼联合替莫唑胺可考虑作为治疗选择之一。
- 治疗期间需密切监测血常规、血压和腹泻等不良事件,并根据中性粒细胞和血小板计数调整替莫唑胺剂量。
局限性
- 单臂设计,缺乏随机对照,结论需进一步随机试验验证。
- 队列2为探索性分析,样本量较小(n=30)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis for patients with unresectable or metastatic soft tissue sarcomas remains poor. Evidence shows that a combination of antiangiogenic agents and chemotherapy inhibit tumour growth. We aimed to investigate the dual targeting of VEGF and MET pathways with cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. METHODS: This multicentre, single-arm, lead-in phase 2 trial was conducted at five academic Sarcoma Centers of Excellence of the Midwest Sarcoma Trials Partnership in the USA. Eligible patients were aged 18 years or older, had histologically-confirmed unresectable or metastatic uterine and non-uterine leiomyosarcoma (cohort 1) and other soft tissue sarcomas (cohort 2; exploratory), an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, up to five previous chemotherapy regimens, adequate organ and bone marrow function, and measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1). Patients received oral cabozantinib 40 mg (as a starting dose) once per day and temozolomide 150 mg/m2 on days 1-5 of a 28-day cycle for cycle one. Starting from cycle two, temozolomide was escalated to 200 mg/m2 on days 1-5 of each cycle, if the absolute neutrophil count was more than 1·5 × 109/L and platelet count was more than 100·0 × 109/L, and treatment continued until disease progression or unacceptable drug-related adverse events. The primary endpoint in cohort 1 was progression-free survival at 12 weeks, assessed in the intention-to-treat population (defined as all enrolled patients). This study is registered with ClinicalTrials.gov, NCT04200443 (completed accrual). FINDINGS: Between Jan 17, 2020, and Feb 6, 2023, 96 patients were assessed for eligibility, 24 were ineligible, and 72 were enrolled. The median age at enrolment was 59 years (IQR 52-66) in cohort 1 (n=42) and 63 years (50-69) in cohort 2 (n=30), with a median follow-up of 18·0 months (17·5-20·7). 42 (58%) of 72 patients were female and 30 (42%) were male. In cohort 1, progression-free survival at 12 weeks was reached by 31 (74%) of 42 patients who were still receiving cabozantinib and temozolomide. The Kaplan-Meier estimate of progression-free survival was higher due to censoring and not requiring patients to be receiving treatment at 12 weeks (79·4% [95% CI 68·6-86·8]). 20 (48%) patients in cohort 1 and 23 (77%) in cohort 2 had died due to disease progression at the end of the study. 71 (99%) of 72 patients had grade 1 or higher treatment-related adverse events. The most common grade 3-4 adverse events attributed to either one or both drugs were platelet count decrease (22 [30%]), neutrophil count decrease (13 [18%]), hypertension (seven [10%]), and diarrhoea (six [8%]). There were no treatment-related deaths. INTERPRETATION: Cabozantinib with temozolomide showed a meaningful clinical benefit and could potentially be a viable treatment option for patients with unresectable or metastatic leiomyosarcoma. Treatment was tolerable and did not reveal any new safety signals. FUNDING: Exelixis.
引用
- Monga V, Okuno S, Van Tine B, et al. Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial. Lancet Oncol. 2026. PMID: 41554272. doi:10.1016/S1470-2045(25)00654-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。